Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals, Inc. (MIRM) Healthcare & Pipeline Overview

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare and orphan diseases. Its lead candidate, LIVMARLI, targets progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. The company also advances Volixibat for intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis, addressing significant unmet medical needs.

What Is the Investment Thesis for MIRM?

Mirum Pharmaceuticals, Inc. presents a focused investment thesis centered on its pipeline of novel therapies for rare and orphan diseases, addressing significant unmet medical needs. The company's lead investigational oral drug, LIVMARLI, targeting progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia, represents potential for substantial market penetration in these specialized indications. Similarly, Volixibat for intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis offers additional growth avenues. While the company currently reports a profit margin of -140.2%, typical for a biopharmaceutical firm in the development and initial commercialization phases, its robust gross margin of 81.4% indicates strong pricing power and cost efficiency once sales scale. With a market capitalization of $6.30B and a Beta of 0.52, Mirum exhibits lower volatility compared to the broader market, potentially appealing to investors seeking exposure to the high-growth biotech sector with a degree of stability. Successful clinical trial outcomes and regulatory approvals for its pipeline candidates are critical catalysts for future value creation.

Based on FMP financials and quantitative analysis

MIRM Key Highlights

• Market capitalization stands at $5.13 billion, reflecting the company's valuation in the specialized biopharmaceutical sector.
• Gross margin of 81.4% demonstrates strong product economics and efficient cost management relative to revenue generated.
• Profit margin of -140.2% is indicative of a company in a significant research, development, and commercialization investment phase, common for biotechnology firms.
• The company employs 334 individuals, focusing resources on specialized rare disease drug development and commercialization efforts.
• A Beta of 0.52 suggests Mirum Pharmaceuticals' stock exhibits lower volatility compared to the overall market, potentially offering relative stability.

Who Are MIRM's Competitors?

MIRM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MIRM's Key Strengths?

• Focused pipeline addressing high unmet medical needs in rare liver and cholestatic diseases.
• Lead product candidate, LIVMARLI, is investigational for multiple significant indications (PFIC, Alagille, biliary atresia).
• Strong gross margin of 81.4% indicates potential for profitability upon scaling commercialization.
• Dedicated team of 334 employees with expertise in rare disease drug development.
• Volixibat in development for additional indications (ICP, PSC), diversifying future revenue streams.

What Are MIRM's Weaknesses?

• Currently unprofitable with a profit margin of -140.2%, typical for biotech but requires significant capital investment.
• Reliance on the successful development and regulatory approval of a limited number of pipeline candidates.
• High costs associated with research, development, and clinical trials for rare disease therapies.
• Market success is heavily dependent on the efficacy and safety profiles of investigational drugs.
• Limited commercialized products, making the company susceptible to pipeline setbacks.

What Could Drive MIRM Stock Higher?

• Potential positive clinical trial results for LIVMARLI in Alagille syndrome, which could support future regulatory submissions and expand its market.
• Regulatory submission or approval milestones for LIVMARLI in biliary atresia disease, opening a new therapeutic market segment.
• Progress in the clinical development of Volixibat for intrahepatic cholestasis of pregnancy (ICP), with data readouts expected to inform future phases.
• Advancement of Volixibat through clinical trials for primary sclerosing cholangitis (PSC), targeting a significant unmet medical need.
• Potential for new strategic partnerships or collaborations that could accelerate the development or commercialization of pipeline assets.

What Are the Key Risks for MIRM?

• Financial-distress signal — its Altman Z-Score of 1.67 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for LIVMARLI or Volixibat could significantly impact the company's pipeline and future revenue prospects.
• Regulatory delays or non-approvals from health authorities for any of its investigational drugs, hindering market entry.
• Intense competition from other biopharmaceutical companies developing therapies for rare liver and cholestatic diseases.
• The company's current negative profit margin (-140.2%) indicates ongoing reliance on capital raises or future product sales to achieve profitability.
• Challenges in market access, pricing, and reimbursement for its specialized therapies in various global healthcare systems.

What Are the Growth Opportunities for MIRM?

• LIVMARLI for Progressive Familial Intrahepatic Cholestasis (PFIC): Mirum Pharmaceuticals is developing LIVMARLI, an investigational oral drug, to address PFIC, a group of rare genetic liver disorders causing severe cholestasis and liver disease. This condition often leads to liver failure and requires transplantation. The potential market for PFIC is significant due to the high unmet medical need for effective, non-surgical treatments. Successful development and commercialization of LIVMARLI for this indication could provide a crucial therapeutic option, potentially improving patient outcomes and establishing a strong market position for Mirum in this specialized area. The timeline for regulatory approval is dependent on ongoing clinical trials.
• LIVMARLI for Alagille Syndrome: The development of LIVMARLI for Alagille syndrome represents another key growth opportunity. Alagille syndrome is a rare genetic disorder that can affect multiple organ systems, including the liver, heart, and kidneys, often leading to chronic liver disease and cholestasis. Patients with Alagille syndrome face significant morbidity and mortality, with limited specific treatment options. Introducing an effective oral therapy like LIVMARLI could substantially improve the quality of life for these patients and reduce the burden of the disease. The market size is defined by the global prevalence of Alagille syndrome, which presents a distinct patient population seeking improved therapeutic interventions.
• LIVMARLI for Biliary Atresia Disease: Mirum's pursuit of LIVMARLI for biliary atresia disease targets a severe and rare liver disease affecting infants, where bile ducts outside and inside the liver are scarred and blocked. This condition leads to bile accumulation in the liver, causing damage and often necessitating liver transplantation. An effective oral treatment for biliary atresia could significantly alter the disease's natural history and improve long-term outcomes for affected children. The opportunity lies in addressing a critical need for non-surgical interventions in a vulnerable patient population, potentially establishing LIVMARLI as a standard of care if successful through clinical development.
• Volixibat for Intrahepatic Cholestasis of Pregnancy (ICP): The development of Volixibat for intrahepatic cholestasis of pregnancy (ICP) addresses a condition that can cause intense itching and carries risks for both mother and fetus. Current management options are limited, and an effective, well-tolerated oral therapy could fill a significant gap in care for pregnant individuals. The market opportunity is driven by the prevalence of ICP globally and the desire for safer and more effective treatments during pregnancy. Successful clinical development and regulatory approval would position Volixibat as a valuable option in maternal-fetal medicine, expanding Mirum's therapeutic reach.
• Volixibat for Primary Sclerosing Cholangitis (PSC): Mirum is also developing Volixibat for primary sclerosing cholangitis (PSC), a chronic, progressive liver disease characterized by inflammation and scarring of the bile ducts, often leading to liver failure and the need for transplantation. There are currently no approved medical therapies that effectively slow the progression of PSC. A successful therapy like Volixibat could represent a major breakthrough for patients, offering a disease-modifying option. The market size for PSC is substantial given its chronic nature and the high unmet need for effective treatments, providing a significant long-term growth driver for Mirum.

What Opportunities Does MIRM Have?

• Expansion of LIVMARLI's approved indications into additional rare liver diseases, increasing patient reach and revenue.
• Successful clinical development and regulatory approval of Volixibat for intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis.
• Potential for orphan drug designations and associated market exclusivity and incentives.
• Strategic partnerships or collaborations to accelerate development or expand commercialization efforts globally.
• Addressing a global market for rare diseases where existing treatment options are often inadequate or non-existent.

What Threats Does MIRM Face?

• Clinical trial failures or unexpected safety concerns could halt or delay drug development.
• Regulatory hurdles and potential non-approvals from health authorities (e.g., FDA, EMA).
• Competition from other biopharmaceutical companies developing similar or alternative therapies for target indications.
• Patent expiry or challenges to intellectual property could erode market exclusivity.
• Market access and reimbursement challenges in different healthcare systems for high-cost rare disease therapies.

What Are MIRM's Competitive Advantages?

• Specialization in rare and orphan diseases, often leading to smaller, less competitive markets and potential for orphan drug designations.
• Proprietary drug candidates like LIVMARLI and Volixibat, which target specific biological pathways relevant to severe liver and cholestatic conditions.
• Extensive clinical development programs and regulatory expertise required to bring novel therapies for rare diseases to market.
• Intellectual property protection (patents) for its drug compounds and methods of use, providing market exclusivity.
• Established relationships within the rare disease patient and physician communities, facilitating clinical trials and commercialization.

What Does MIRM Do?

Mirum Pharmaceuticals, Inc., incorporated in 2018 and headquartered in Foster City, California, operates as a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for debilitating rare and orphan diseases. The company's strategic focus is on conditions with high unmet medical needs, aiming to provide transformative treatment options for patient populations often underserved by existing pharmaceutical solutions. Mirum's flagship product candidate is LIVMARLI, an investigational oral drug. LIVMARLI is currently under development for multiple indications, including progressive familial intrahepatic cholestasis disease (PFIC), a group of rare genetic disorders causing impaired bile flow; Alagille syndrome, a genetic disorder affecting multiple organ systems, notably the liver; and biliary atresia disease, a rare disease of the liver and bile ducts that occurs in infants. These conditions represent significant challenges for patients and healthcare providers, often leading to severe complications and requiring complex management. Beyond LIVMARLI, Mirum Pharmaceuticals is also advancing Volixibat, another promising drug candidate. Volixibat is being developed for the treatment of intrahepatic cholestasis of pregnancy (ICP), a liver condition that can occur during pregnancy, and primary sclerosing cholangitis (PSC), a chronic liver disease that damages the bile ducts. With a team of 334 employees, Mirum Pharmaceuticals leverages its expertise in rare disease drug development to address critical therapeutic gaps and improve patient outcomes in specialized medical areas.

What Products and Services Does MIRM Offer?

• Develops novel therapies for debilitating rare and orphan diseases.
• Focuses on conditions with high unmet medical needs in specialized patient populations.
• Advances LIVMARLI, an investigational oral drug, for progressive familial intrahepatic cholestasis disease (PFIC).
• Investigates LIVMARLI for the treatment of Alagille syndrome, a rare genetic disorder affecting the liver.
• Explores LIVMARLI's potential for biliary atresia disease, a severe pediatric liver condition.
• Develops Volixibat for intrahepatic cholestasis of pregnancy (ICP), a liver condition in pregnant individuals.
• Researches Volixibat for primary sclerosing cholangitis (PSC), a chronic liver disease.
• Conducts clinical trials and seeks regulatory approvals for its drug candidates.

How Does MIRM Make Money?

• Primarily generates revenue through the commercialization of approved rare disease therapies.
• Invests heavily in research and development to discover and advance novel drug candidates through clinical trials.
• Aims to secure regulatory approvals (e.g., FDA, EMA) for its investigational drugs to bring them to market.
• Focuses on specialized markets for rare and orphan diseases, which often allow for premium pricing and extended market exclusivity.
• Engages in commercialization efforts, including sales and marketing, once drugs receive regulatory clearance.

What Industry Does MIRM Operate In?

Mirum Pharmaceuticals, Inc. operates within the highly specialized Biotechnology industry, a sub-segment of the broader Healthcare sector. This industry is characterized by extensive research and development, lengthy clinical trial processes, and significant regulatory hurdles. Mirum's strategic focus on rare and orphan diseases positions it within a niche market segment that often benefits from expedited regulatory pathways and premium pricing due to high unmet medical needs and smaller patient populations. The competitive landscape includes other biopharmaceutical companies developing therapies for liver diseases and rare genetic disorders, such as Praxis Precision Medicines, Inc. (PRAX), Belite Bio, Inc. (BLTE), Ligand Pharmaceuticals Incorporated (LGND), and Travere Therapeutics, Inc. (TVTX). Mirum aims to differentiate itself through novel mechanisms of action and targeted therapies for specific, severe conditions, seeking to establish leadership in these specialized therapeutic areas.

Who Are MIRM's Key Customers?

• Patients diagnosed with progressive familial intrahepatic cholestasis disease (PFIC).
• Individuals suffering from Alagille syndrome and biliary atresia disease.
• Pregnant individuals experiencing intrahepatic cholestasis of pregnancy (ICP).
• Patients with primary sclerosing cholangitis (PSC).
• Healthcare providers, including hepatologists, gastroenterologists, pediatricians, and obstetricians, who treat these rare conditions.

How Mirum Pharmaceuticals, Inc. Is Valued

Mirum Pharmaceuticals, Inc. carries a market capitalization of $6.30B, placing it in the mid-cap category. Relative to its peer group, MIRM's quantitative score of 24/100 is below the peer average of 66/100.

Company Profile

Mirum Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Foster City, US. The company is led by CEO Christopher Peetz. MIRM has traded publicly since 2019.

Key Financial Metrics

Return on assets is -89.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Mirum Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.67 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Mirum Pharmaceuticals, Inc. revenue of about $674.5M for fiscal 2026, with EPS near $-15.65. The estimate reflects 9 contributing analysts.

MIRM Financials

MIRM Latest News

MIRM Analyst Consensus

MIRM MoonshotScore

Mirum Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources